**WHAT IS MEDSPAL?**
Developed by the Medicines Patent Pool (MPP), the database offers an overview of the intellectual property status of approximately **100** medicines in **130** developing countries.

**WHAT DOES MEDSPAL CONTAIN?**

**PATENT DATA**
Granted patents and pending patent applications relating to specific medicinal formulations, with:
- bibliographical details
- legal status (e.g. filed, granted, opposed, expired)
- expected expiry dates
- links to actual patent documents on Espacenet, the European Patent Office public database

**LICENCE INFORMATION**
Information on patent licences that enable generic access in LMICs:
- licences negotiated by the MPP (with links to the full licences)
- bilateral licences between originators and generics
- public commitments not to enforce patents
- compulsory licences, if publicly available

**DATA EXCLUSIVITY**
Information on data exclusivity protection from 15 countries from National regulatory authorities with expiry date.

**HOW IS MEDSPAL UPDATED?**
- automated data feeds
- online searches
- patent holder disclosures (MPP licenses, Pat-Informed, disclosures to patent offices)
- collaborations with patent experts
- collaborations with national/regional patent offices (collaboration agreements)
SEARCH VIEW - Search by keywords, products and/or countries

Search by keywords, products and/or countries

MAP VIEW - Search by formulation

Data Exclusivity

Test data exclusivity until 29/12/2019

Licence(s):
MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations
MPP licence on paediatric formulations of dolutegravir (DTG)

Data Exclusivity

Patent Information

Expected Expiry Date (dd/mm/yyyy)


Ukraine | Dolutegravir 50 mg | Dolutegravir and Cabotegravir compounds | Term extended | UA2007011345

Vietnam | Dolutegravir 50 mg | Dolutegravir and Cabotegravir compounds | Granted | VN201300151

Licence Information

Licence(s):
MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations
MPP licence on paediatric formulations of dolutegravir (DTG)

Patent and Licensing Status of approx. 100 priority medicines in low- & middle-income countries
COLLABORATIONS WITH REGIONAL AND NATIONAL PATENT OFFICES

To collect and update the data in MedsPal, the MPP has signed collaboration agreements with the following regional and national patent offices:

African Regional Intellectual Property Organization (ARIPO), the Eurasian Patent Office (EAPO), the European Patent Office (EPO)

National patent offices of Argentina (INPI), Brazil (INPI), Chile (INAPI), Dominican Republic (ONAPI), Ecuador (SENADI), Egypt (EGPO), El Salvador (CNR), Peru (INDECOPI), South Africa (CIPC) and Uruguay (DNPI).

WHY MEDSPAL?

MedsPaL seeks to address the challenges faced when seeking patent information on medicines such as:

- The complexity of patent documents and patent procedures
- The technical and legal knowledge required to search and assess patent documents
- The need to go to each national patent office to check the patent status
- Electronic national patent registers not always available
- National registers may only be available in the national language and may not include patent status

WHAT IS MEDSPAL USED FOR?

The tool is widely used by key public health actors for the purposes of:

- Procurement of medicines
- Investment/supply of medicines
- Policy analysis and policy-making
- Access strategies
- Advocacy

The MPP looks forward to expanding its network of collaborating patent offices. National or regional patent offices interested in partnering may contact:

medspal@medicinespatentpool.org

MedsPaL is a database hosted by the Medicines Patent Pool, a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low- and middle-income countries through voluntary licensing and patent pooling. The organisation’s HIV, hepatitis C and TB activities are fully funded by Unitaid. Funding provided by the Swiss Agency for Development and Cooperation (SDC) made the upgrade of MedsPaL to include other essential medicines possible.